Cargando…
A potent phosphodiester Keap1-Nrf2 protein-protein interaction inhibitor as the efficient treatment of Alzheimer's disease
The Keap1-Nrf2 pathway has been established as a therapeutic target for Alzheimer's disease (AD). Directly inhibiting the protein-protein interaction (PPI) between Keap1 and Nrf2 has been reported as an effective strategy for treating AD. Our group has validated this in an AD mouse model for th...
Autores principales: | Sun, Yi, Xu, Lijuan, Zheng, Dongpeng, Wang, Jue, Liu, Guodong, Mo, Zixin, Liu, Chao, Zhang, Wannian, Yu, Jianqiang, Xing, Chengguo, He, Ling, Zhuang, Chunlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331597/ https://www.ncbi.nlm.nih.gov/pubmed/37385075 http://dx.doi.org/10.1016/j.redox.2023.102793 |
Ejemplares similares
-
Emerging Screening Approaches in the Development of Nrf2–Keap1 Protein–Protein Interaction Inhibitors
por: Leung, Chung-Hang, et al.
Publicado: (2019) -
Zwitterionic Phosphodiester-Substituted Neoglycoconjugates
as Ligands for Antibodies and Acute Phase Proteins
por: Labrada, Karell Pérez, et al.
Publicado: (2020) -
CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation
por: Lu, Meng-Chen, et al.
Publicado: (2019) -
Keap1-Independent Regulation of Nrf2 Activity by Protein Acetylation and a BET Bromodomain Protein
por: Chatterjee, Nirmalya, et al.
Publicado: (2016) -
KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential
por: Crisman, Enrique, et al.
Publicado: (2022)